BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Tzanaki I, Agouridis AP, Kostapanos MS. Is there a role of lipid-lowering therapies in the management of fatty liver disease? World J Hepatol 2022; 14(1): 119-139 [PMID: 35126843 DOI: 10.4254/wjh.v14.i1.119]
URL: https://www.wjgnet.com/1948-5182/full/v14/i1/119.htm
Number Citing Articles
1
Reda Albadawy, Amany Helmy Hasanin, Sara H. A. Agwa, Shaimaa Hamady, Yasmin M. Aboul-Ela, Mona Hussien Raafat, Samaa Samir Kamar, Mohamed Othman, Yahia A. Yahia, Marwa Matboli. Rosavin Ameliorates Hepatic Inflammation and Fibrosis in the NASH Rat Model via Targeting Hepatic Cell DeathInternational Journal of Molecular Sciences 2022; 23(17): 10148 doi: 10.3390/ijms231710148
2
Jialei Fu, Sangah Shin. Dietary patterns and risk of non-alcoholic fatty liver disease in Korean adults: a prospective cohort studyBMJ Open 2023; 13(1): e065198 doi: 10.1136/bmjopen-2022-065198
3
Vitalina V. Ivachevska, Mykhailo M. Ivachevskyi, Mykhailo M. Hechko, Ivan I. Myhovych, Olga S. Blaga. EFFICACY OF COMPREHENSIVE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH PREDIABETESWiadomości Lekarskie 2023; 76(3): 581 doi: 10.36740/WLek202303119
4
Lin Jia. Dietary cholesterol in alcohol-associated liver diseaseImmunometabolism 2023; 5(2): e00026 doi: 10.1097/IN9.0000000000000026
5
强江 郭. Research Progress of Traditional Chinese Medicine and Western Medicine on Non-Alcoholic Fatty Liver DiseaseAdvances in Clinical Medicine 2024; 14(03): 561 doi: 10.12677/ACM.2024.143739
6
Mohammad Sadiq Jeeyavudeen, Shahanas K A Khan, Sherouk Fouda, Joseph M Pappachan. Management of metabolic-associated fatty liver disease: The diabetology perspectiveWorld Journal of Gastroenterology 2023; 29(1): 126-143 doi: 10.3748/wjg.v29.i1.126
7
Ramiro Manzano‐Nunez, Jesús Rivera‐Esteban, Jordi Navarro, Juan Bañares, Elena Sena, Jörn M. Schattenberg, Jeffrey V. Lazarus, Adria Curran, Juan M. Pericàs. Uncovering the NAFLD burden in people living with HIV from high‐ and middle‐income nations: a meta‐analysis with a data gap from Subsaharan AfricaJournal of the International AIDS Society 2023; 26(3) doi: 10.1002/jia2.26072
8
Stefania Cannito, Umberto Dianzani, Maurizio Parola, Emanuele Albano, Salvatore Sutti. Inflammatory processes involved in NASH-related hepatocellular carcinomaBioscience Reports 2023; 43(1) doi: 10.1042/BSR20221271
9
Zahra Eslami, Samaneh Sadat Aghili, Amir Ghaleh Ghafi. Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease PatientsChonnam Medical Journal 2024; 60(1): 13 doi: 10.4068/cmj.2024.60.1.13
10
Paolo Raggi, Jovana Milic, Marcella Manicardi, Felice Cinque, Mark G. Swain, Giada Sebastiani, Giovanni Guaraldi. Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatologyAtherosclerosis 2024; 392: 117523 doi: 10.1016/j.atherosclerosis.2024.117523
11
J. Fu, Z. Mu, L. Sun, X. Gao, X. Hu, S. Xiu. Chinese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease have lower serum osteocalcin levels compared to individuals with type 2 diabetes mellitus and no liver disease: a single-center cross-sectional studyJournal of Endocrinological Investigation 2022; 45(12): 2275 doi: 10.1007/s40618-022-01861-z
12
Shuai Yuan, Jie Chen, Marijana Vujkovic, Kyong-Mi Chang, Xue Li, Susanna C Larsson, Dipender Gill. Effects of metabolic traits, lifestyle factors, and pharmacological interventions on liver fat: mendelian randomisation studyBMJ Medicine 2022; 1(1): e000277 doi: 10.1136/bmjmed-2022-000277
13
Anna Licata, Giuseppina T. Russo, Annalisa Giandalia, Marcella Cammilleri, Clelia Asero, Irene Cacciola. Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 DiabetesJournal of Personalized Medicine 2023; 13(3): 558 doi: 10.3390/jpm13030558